TrialAmerican journal of clinical oncology2018

A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.

Dana B Cardin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.